Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group

Hans Erik Johnsen; Tobias W Klausen; Martin Boegsted; Stig Lenhoff; Peter Gimsing; Ilse Christiansen; Tobias Gedde-Dahl; Roald Lindås; Ulf-Henrik Mellqvist; Nordic Myeloma Study Group

doi:10.3816/CLML.2010.n.060

Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group

Hans Erik Johnsen, Tobias W Klausen, Martin Boegsted, Stig Lenhoff, Peter Gimsing, Ilse Christiansen, Tobias Gedde-Dahl, Roald Lindås, Ulf-Henrik Mellqvist, Nordic Myeloma Study Group

3 Citations (Scopus)

Abstract

An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.

Original language	English
Journal	Clinical Lymphoma & Myeloma
Volume	10
Issue number	4
Pages (from-to)	290-6
Number of pages	7
ISSN	1557-9190
DOIs	https://doi.org/10.3816/CLML.2010.n.060
Publication status	Published - 1 Aug 2010

Access to Document

10.3816/CLML.2010.n.060

Fingerprint

Dive into the research topics of 'Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group'. Together they form a unique fingerprint.

Cite this

Johnsen, H. E., Klausen, T. W., Boegsted, M., Lenhoff, S., Gimsing, P., Christiansen, I., Gedde-Dahl, T., Lindås, R., Mellqvist, U.-H., & Nordic Myeloma Study Group (2010). Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group. Clinical Lymphoma & Myeloma, 10(4), 290-6. https://doi.org/10.3816/CLML.2010.n.060

Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group. / Johnsen, Hans Erik; Klausen, Tobias W; Boegsted, Martin et al.
In: Clinical Lymphoma & Myeloma, Vol. 10, No. 4, 01.08.2010, p. 290-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Johnsen, HE, Klausen, TW, Boegsted, M, Lenhoff, S, Gimsing, P, Christiansen, I, Gedde-Dahl, T, Lindås, R, Mellqvist, U-H & Nordic Myeloma Study Group 2010, 'Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group', Clinical Lymphoma & Myeloma, vol. 10, no. 4, pp. 290-6. https://doi.org/10.3816/CLML.2010.n.060

Johnsen HE, Klausen TW, Boegsted M, Lenhoff S, Gimsing P, Christiansen I et al. Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group. Clinical Lymphoma & Myeloma. 2010 Aug 1;10(4):290-6. doi: 10.3816/CLML.2010.n.060

Johnsen, Hans Erik ; Klausen, Tobias W ; Boegsted, Martin et al. / Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group. In: Clinical Lymphoma & Myeloma. 2010 ; Vol. 10, No. 4. pp. 290-6.

@article{dd0c3b73835b4b98bca4ce77f0bb703d,

title = "Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group",

abstract = "An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.",

author = "Johnsen, \{Hans Erik\} and Klausen, \{Tobias W\} and Martin Boegsted and Stig Lenhoff and Peter Gimsing and Ilse Christiansen and Tobias Gedde-Dahl and Roald Lind{\aa}s and Ulf-Henrik Mellqvist and \{Nordic Myeloma Study Group\}",

year = "2010",

month = aug,

day = "1",

doi = "10.3816/CLML.2010.n.060",

language = "English",

volume = "10",

pages = "290--6",

journal = "Clinical Lymphoma \& Myeloma",

issn = "1557-9190",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group

AU - Johnsen, Hans Erik

AU - Klausen, Tobias W

AU - Boegsted, Martin

AU - Lenhoff, Stig

AU - Gimsing, Peter

AU - Christiansen, Ilse

AU - Gedde-Dahl, Tobias

AU - Lindås, Roald

AU - Mellqvist, Ulf-Henrik

AU - Nordic Myeloma Study Group

PY - 2010/8/1

Y1 - 2010/8/1

N2 - An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.

AB - An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.

UR - https://www.scopus.com/pages/publications/77957070224

U2 - 10.3816/CLML.2010.n.060

DO - 10.3816/CLML.2010.n.060

M3 - Journal article

C2 - 20709667

SN - 1557-9190

VL - 10

SP - 290

EP - 296

JO - Clinical Lymphoma & Myeloma

JF - Clinical Lymphoma & Myeloma

IS - 4

ER -

Abstract

Access to Document

Other files and links

Fingerprint

Cite this